Adaptive Biotechnologies (ADPT) EBT Margin (2018 - 2026)

Adaptive Biotechnologies has disclosed EBT Margin across 9 years of filings, most recently posting 28.24% for Q1 2026.

• EBT Margin for Q1 2026 came in at 28.24%, up 2864.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.8% (up 5806.0% YoY), and the FY2025 annual result was 21.47%, up 6771.0% from the prior year.
• EBT Margin came in at 28.24% for Q1 2026 at Adaptive Biotechnologies, down from 18.94% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 10.16% in Q3 2025 to a low of 620.92% in Q2 2023.
• The 5-year median for EBT Margin is 94.75% (2022), against an average of 118.01%.
• Across the five-year window, EBT Margin slumped 50163 bps in 2023 and soared 51384 bps in 2024, its largest moves.
• Adaptive Biotechnologies' EBT Margin stood at 72.77% in 2022, then sank by 108 bps to 151.73% in 2023, then soared by 53 bps to 71.04% in 2024, then jumped by 73 bps to 18.94% in 2025, then slumped by 49 bps to 28.24% in 2026.
• The last three EBT Margin figures came in at 28.24% (Q1 2026), 18.94% (Q4 2025), and 10.16% (Q3 2025), per Business Quant data.